

Vitamin A supplementation prevents the bronchopulmonary dysplasia in premature infants A systematic review and meta-analysis

Yuegin Ding, MD^{*}, Zhifeng Chen, MD, Yanling Lu, PhD

Abstract

Background: It is necessary to evaluate the effectiveness and safety of vitamin A supplementation on the bronchopulmonary dysplasia (BPD) in premature infants.

Methods: Randomized controlled trials (RCTs) on the role of supplemental vitamin A in preterm infants were searched. The Medline et al databases were manually searched from inception to April 30, 2020. Related outcomes including incidence of BPD, retinopathy of prematurity (ROP), necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), sepsis and mortality were assessed with Review Manager 5.3 software, and Random-effect model was applied for all conditions.

Results: A total of 9 RCTs with 1409 patients were included. The analyzed results showed that the incidence of BPD in vitamin A group was significantly less than that of control group (OR = 0.67, 95%CI [0.52–0.88]). There was no significant difference in the incidence of ROP (OR = 0.65, 95%CI [0.29–1.48]), NEC (OR = 0.88, 95%CI [0.59–1.30]), IVH (OR = 0.90, 95%CI [0.65–1.25]), sepsis (OR = 0.84, 95%CI [0.64–1.09]) and mortality (OR = 0.98, 95%CI [0.72–1.34]) among two groups.

Conclusion: Vitamin A supplementation is beneficial to the prophylaxis of BPD in premature infants, further studies on the administration approaches and dosages of vitamin A in premature infants are warranted.

Abbreviations: BPD = bronchopulmonary dysplasia, CI = confidence interval, CNKI = China National Knowledge Infrastructure, IVH = intraventricular hemorrhage, NEC = necrotizing enterocolitis, OR = odd of risk, PRISMA = Preferred Reporting Items for Systematic Review and Meta-Analysis, RCTs = randomized controlled trials, ROP = retinopathy of prematurity.

Keywords: bronchopulmonary dysplasia, infant, premature, vitamin A

1. Introduction

Bronchopulmonary dysplasia (BPD) is one of the most common chronic diseases of premature infants.^[1] Not only does the mortality rate are high, but also the impact on surviving children may last for life, bringing a heavy burden on the children's physical and mental health, family, and society.^[2] Moreover, the incidence of BPD is also increasing.^[3] Scholars such as Northway

Editor: Zhongheng Zhang.

The authors have no funding information to disclose.

The authors have no conflicts of interests to disclose.

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

Neonatal Intensive Care Unit, Dongguan People's Hospital, Dongguan 523000, Guangdong Province, P.R. China.

^{*} Correspondence: Yueqin Ding, Neonatal Intensive Care Unit, Dongguan People's Hospital, No.3 Wangdao Road, Dongguan 523000, Guangdong Province, P.R. China (e-mail: wozonghuimutun@163.com).

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Ding Y, Chen Z, Lu Y. Vitamin A supplementation prevents the bronchopulmonary dysplasia in premature infants: A systematic review and meta-analysis. Medicine 2021;100:3(e23101).

Received: 22 June 2020 / Received in final form: 16 September 2020 / Accepted: 12 October 2020

http://dx.doi.org/10.1097/MD.00000000023101

first proposed the concept of BPD in 1967.^[4] For more than 50 years, humans have conducted a lot of research on the prevention and treatment of BPD. Although many progresses have been made, there is currently no definite and effective treatment, and its prevention is especially important.

Many studies^[5,6] have shown that vitamin A may be beneficial for the prevention of BPD. As early as 1987, a double-blind randomized controlled trial (RCT)^[7] showed that supplementing vitamin A can reduce the incidence of BPD. However, recently some scholars have proposed the opposite point of view, it is believed that vitamin A is ineffective in preventing BPD and increases the risk of sepsis in children.^[7] Tolia et al^[8] have also founded that the neonatal death and the occurrence of BPD may not be affected by recent vitamin A deficiency. It can be seen that whether vitamin A can prevent the occurrence of BPD is still controversial. Previous meta-analyses^[9,10] have compared the effects and safety of vitamin A in the premature infants, yet the results have remained inconsistent. Furthermore, the sample size is rather small. Therefore, an updated meta-analysis on the role of vitamin A in the premature infants is needed. In this present study, we aimed to comprehensively evaluate the effectiveness and safety of supplemental vitamin A in preterm infants, to provide a reference for clinical management of premature infants.

2. Methods

This systematic review and meta-analysis did not pre-registered on the website, and it was reported in following of the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines.^[11]

2.1. Eligibility criteria

Studies were included in this present review if following PICOS criteria were met:

- 1. Participants: Preterm infants (gestational age <37 weeks) without congenital abnormalities.
- 2. Intervention: trials that compared patients who received vitamin A vs did not receive vitamin A supplementation.
- 3. Outcomes: related outcomes on the effects and safety were reported, including the incidence of BPD, retinopathy of prematurity (ROP), necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), sepsis, and mortality.
- 4. Design: RCT, published in a peer reviewed journal.

The literature exclusion criteria were:

- 1. The quality of the literature was poor, including serious flaws in research design, improper random methods, etc.
- For the same study which was published multiple times, the one with the largest sample size was taken, and others were excluded;
- 3. Unable to obtain the original text or not get sufficient original data for meta-synthesis

Literature search strategy

The Medline, Science Direct, Cochrane Central Register of Controlled Trials, EMBASE, China National Knowledge Infrastructure (CNKI) and Wanfang database were manually searched from inception to April 30, 2020. We used the combination of subject words and free words to perform the search process. The search terms were as follows: (vitamin A OR Vit A OR V A) AND (premature or preterm or neonate or newborn or infant or epilepsy). There were no language restrictions applied during the search process in this present study.

2.3. Data extraction

The two reviewers independently screened the literatures according to the inclusion and exclusion criteria, and used the same data extraction table to extract the data and check with each other. If there were disagreements, they were resolved through discussion or decided by the third researcher. The extracted information included:

- 1. The first author, the year of publication, the country, and other basic information of the included literature;
- Research methods and key elements of RCT for the bias risk assessment;
- 3. interventions, including the time, route, dose, and duration of treatment course;
- 4. related outcomes: the incidence of BPD, ROP, NEC, IVH, sepsis, and mortality.

The assessment on the quality of included RCTs

The qualities of related RCTs were independently evaluated by two of our reviewers. And any conflicting results were further judged by another author. We used Cochrane Collaboration's tool of bias risk^[12] to assess the methodological quality and potential risk of bias in the included RCTs. This tool includes seven specific domains: sequence generation, assignment hiding, blindness of participants and personnel, blindness of outcome evaluation, incomplete result data, selective result reporting, and other issues. According to the judgment criteria, each domain is classified as low bias risk, high bias risk, or unclear bias risk. Statistical analysis All the statistical analyses were conducted using the Review Manager 5.3 software (Copenhagen). The odd of risk (OR) with related 95% confidence intervals (CI) was calculated to estimate the synthesized effects of included RCTs. Furthermore, the statistical heterogeneity was evaluated with *Q*-test and I^2 , and the I^2 values of 25%, 50%, and 75% were taken as being lowly, moderately, and highly heterogeneous respectively. Randomeffect model were applied for all conditions. Subgroup analysis based on intervention differences were conducted to ascertain the potential origin of heterogeneity. Furthermore, sensitivity analysis was performed by neglecting one study at one time and evaluating the influence of each included RCTs. For all the statistical analyses in this present meta-analysis, P < .05 was taken as statistical significance, and all examined tests were two-sided.

3. Results

3.1. Study selection

The selection process is presented in Figure 1. The initial search resulted in 161 potentially relevant articles. After reviewing the titles and abstracts of the remaining 104 studies after duplicate exclusion, the full text of 25 studies was retrieved. After careful and discreet evaluation based on the included and excluded criteria, 9 RCTs were included finally.

3.2. The characteristics of included RCTs

A total of 9 RCTs^[7,13–20] with 1409 patients were included, of whom 709 infants received vitamin A treatment, and 700 infants did not receive vitamin A treatment. The characteristics of included RCTs were presented in Table 1. Five reported RCTs^[7,15,16,18,20] were conducted in the United States, two^[14,19] in England, and one in Thailand^[13] and China,^[17] respectively. And dose of vitamin A regimens varied from 1500 to 10,000 IU, and the treatment durations generally lasted for 4 weeks.

3.3. Literature quality evaluation

The quality of included 9 RCTs were presented in Figures 2 and 3. Although each study mentioned randomization, and four RCTs^[7,14,16,20] did not mention a specific random method, and there might be pseudo-randomness. Two RCTs^[17,20] did not explicitly reported the distribution and concealment or whether to use blind method. One study^[20] did not report the type and number of specific adverse reactions in detail, and the remaining four studies all reported that. No other significant biases were detected.

3.4. Synthesized outcomes

The incidence of BPD Six RCTs^[7,13,15,16,18,19] reported the incidence of BPD among two groups. No significant heterogeneity was found among included RCTs ($I^2=0\%$). The analysis result showed that the incidence of BPD in the vitamin A group was significantly less than that of control group (OR = 0.67, 95% CI [0.52–0.88], Fig. 4A).

The incidence of ROP Four RCTs^[7,13,14,19] reported the incidence of ROP among two groups. No significant heterogeneity was found among included RCTs ($I^2=53\%$). The analysis result showed that there was no significant difference in the incidence of ROP among two groups (OR=0.65, 95%CI [0.29–1.48], Fig. 4B).




Figure 1. The flow chart of study selection.

The incidence of NEC Three RCTs^[13,16,18] reported the incidence of NEC among two groups. No significant heterogeneity was found among included RCTs ($I^2=0\%$). The analysis result showed that there was no significant difference in the incidence of NEC among two groups (OR=0.88, 95%CI [0.59–1.30], Fig. 4C).

The incidence of IVH Four RCTs^[13,14,18,19] reported the incidence of IVH among two groups. No significant heterogeneity was found among included RCTs ($I^2=0\%$). The analysis


Table 1

result showed that there was no significant difference in the incidence of IVH among two groups (OR = 0.90, 95%CI [0.65-1.25], Fig. 4D).

The incidence of sepsis Three RCTs^[13,18,19] reported the incidence of sepsis among two groups. No significant heterogeneity was found among included RCTs ($I^2 = 0\%$). The analysis result showed that there was no significant difference in the incidence of sepsis among two groups (OR=0.84, 95%CI [0.64–1.09], Fig. 4E).

| The characterist | tics of inclue Countries | ded RCTs. Sample (vit A/control) | Gestational age (w) | Birth weight (g) | Interventions | | | | | |
|-------------------|-----------------------------|--|------------------------|---------------------|--------------------|------------------|---|--|--|--|
| | | | | | Vit A group | Control group | Frequency and duration | | | |
| Kiatchoosaku 2014 | Thailand | 40/40 | 24–32 | <1500 | im, 5000 IU | None | 3/w, 4w | | | |
| Mactier 2012 | England | 42/47 | <32 | <1501 | im, 10,000 IU | None | 3/w, 2~4w | | | |
| Pearson 1992 | USA | 27/22 | 27 <u>+</u> 1 | 700-1100 | im, 2000 IU | Normal saline | Once every other day, a total of 14 times | | | |
| Ravishankar 2003 | USA | 22/18 | <32 | 500-1500 | im, 1500–3000 IU | None | The 1st, 3rd, 7th day after birth | | | |
| Shenai 1987 | USA | 20/20 | 26-30 | 700–1300 | im, 2000 IU | Normal saline | Once every other day, a total of 14 times | | | |
| Tyson 1999 | USA | 405/402 | <30 | 401-1000 | im, 5000 IU | None | 3/w, 4w | | | |
| Wardle 2001 | England | 77/77 | 25-27 | <1000 | po, 2000 IU | Placebo | 1/d, 28d | | | |
| Werkman 1994 | USA | 44/42 | <31 | 725-1300 | iv gtt, 210~476 RE | None | 1/d, 4w | | | |
| Tang 2016 | China | 32/32 | 27-33 | <1500 | po, 5000 IU/kg | None | 1/d, 4w | | | |

3








Figure 3. Risk of bias summary.

The mortality Seven RCTs^[7,13,15-19] reported the mortality among two groups. No significant heterogeneity was found among included RCTs ($I^2 = 0\%$). The analysis result showed that there was no significant difference in the mortality among two groups (OR = 0.98, 95% CI [0.72–1.34], Fig. 4F).

3.5. Sensitivity analysis

The sensitivity analyses were performed by excluding single RCT one by one. The results of sensitivity analysis of all outcomes had indicated no substantial result changes among the overall estimates.


3.6. Publication bias


The publication bias was evaluated with funnel plot. The funnel plots (Fig. 5) for all synthesized outcomes remained symmetrical, indicating that there was no significant publication bias.

4. Discussion

Vitamin A deficiency is a global public health problem.^[21] Vitamin A is mainly transmitted from the mother through the placenta to the fetus in the third trimester. Therefore, the deficiency vitamin A is prevalent in premature infants.^[22] Premature birth and low birth weight are important risk factors for BPD.^[23] The prevalence of BPD in preterm infants with birth weights of 501 to 750g, 1000g, 1250g, and 1500g were 42%, 25%, 11%, and 5%, respectively.^[24] Another study^[25] has reported that 97% preterm infants with birth weight <1250g have BPD. The Canadian Newborn Collaboration^[26] reported that the incidence of BPD among surviving infants with a gestational age of <25 weeks was 28.1%, while the incidence of BPD was only 4% for infants born with a gestational age of 29 to 32 weeks. Previous studies^[27,28] have shown that in the neonates with younger gestational age and the lower birth weight, the vitamin A deficiency is more serious. Meanwhile, BPD is also mainly seen in premature infants with low gestational age,^[29] suggesting that there may be a relationship between the vitamin A deficiency and BPD. The results of this present meta-analysis have revealed that the vitamin A supplementation can reduce the occurrence of BPD in premature infants, even rough no significant differences on the incidence of ROP, NEC, IVH, sepsis, and mortality were found.

| | Vit A | | Contr | | 101-1-1 | Odds Ratio | | | Ratio | |
|---|---|--|---|--|---|---|---|---|---|----------|
| Study or Subgroup | Events | | | 2.62 | Weight | M-H. Random. 95% CI | | M-H. Rand | om. 95% Cl | |
| Kiatchoosaku 2014 | 9 | 38 | 14 | 39 | 7.0% | 0.55 [0.21, 1.50] | | | - | |
| Pearson 1992 | 12 | 26 | 8 | 18 | 4.7% | 1.07 [0.32, 3.59] | | | | |
| Ravishankar 2003 | 4 | 17 | 5 | 14 | 2.8% | 0.55 [0.12, 2.65] | | | | |
| Shenai 1987 | 9 | 19 | 17 | 20 | 3.0% | 0.16 [0.03, 0.73] | | | | |
| yson 1999 | 163 | 346 | 193 | 347 | 77.0% | 0.71 [0.53, 0.96] | | | | |
| Wardle 2001 | 43 | 52 | 42 | 48 | 5.5% | 0.68 [0.22, 2.09] | | | | |
| otal (95% CI) | 1000 | 498 | 100 | 486 | 100.0% | 0.67 [0.52, 0.88] | | ٠ | | |
| Total events | 240 | 1.00 | 279 | - 0.50 | 12 - 00/ | | _ | | | |
| leterogeneity: Tau ² = fest for overall effect: | | | | = 0.50 | i); i ⁻ = 0% | | 0.05 | 0.2 | 5 Favours [contro | 20 |
| | | | The fo | orest | plot for | the incidence of E | BPD | r avouis [vit A] | r avours [contro | N] |
| | Vit A | i. | Contr | | pieriei | Odds Ratio | | Odd | Ratio | |
| Study or Subaroup | Events | | | 100 million - 100 million | Weight | M-H. Random. 95% C | 1 | | lom. 95% Cl | |
| Kiatchoosaku 2014 | 3 | 40 | 7 | 40 | 19.5% | 0.38 [0.09, 1.60] | _ | - | - | |
| Aactier 2012 | 11 | 42 | 14 | 47 | 29.7% | 0.84 [0.33, 2.12] | | | | |
| | | 20 | | | | | _ | | | |
| Shenai 1987 Vardle 2001 | 5 | 77 | 12 | 20 77 | 20.8% 30.0% | 0.22 [0.06, 0.86] | | | | |
| varule 2001 | 15 | " | 9 | | 30.0% | 1.53 [0.61, 3.84] | | | | |
| otal (95% CI) | | 179 | | 184 | 100.0% | 0.65 [0.29, 1.48] | | - | | |
| fotal events leterogeneity: Tau ² = | 32 = 0.36: Chi ² | = 6 27 | 42 | = 0.00 | 2). 12 = 520/ | e | - | 1 1 | | - |
| Test for overall effect: | | | | - 0.05 | , I" = 53% | | 0.1 | 0.2 0.5 Favours IVit A | 1 2 5 Favours [contri | 10 10 |
| 1 | | | The fo | rest | olot for t | he incidence of R | ROP | arous frink | arouro poond | - 4 |
| | Vit | | Cont | | | Odds Ratio | | Odd | s Ratio | |
| Study or Subaroup | | | | | Weight | M-H. Random. 95% C | 1 | | dom. 95% CI | |
| Kiatchoosaku 2014 | 7 | 40 | 8 | | TO BLE STORE | 0.85 [0.28, 2.61] | | | - | |
| Ravishankar 2003 | 1 | 22 | 2 | | | 0.38 [0.03, 4.58] | | | - | |
| Tyson 1999 | 47 | 405 | 51 | 402 | | 0.90 [0.59, 1.38] | | | - | |
| 130111333 | 4/ | 405 | 51 | 402 | 00.0% | 0.90 [0.59, 1.38] | | 1.0 | Т | |
| Total (95% CI) | | 467 | | 460 | 100.0% | 0.88 [0.59, 1.30] | | | | |
| Total events | 55 | | 61 | | | (1) / (() / () / () / () / () / () / () | | | 1 | |
| Heterogeneity: Tau ² | 1.000 | = 0.45 | | P = 0.8 | 0); $l^2 = 0\%$ | | - | 1 | <u> </u> | - |
| | | | | | | | | 0.1 | 1 1 | |
| Test for overall effect | t: Z = 0.65 (| P = 0.5 | 1) | | V2. | | 0.02 | Faussian B.C. A | Equation for | |
| | t: Z = 0.65 (| | | ract | lot for t | he incidence of N | Contraction. | Favours [Vit A | Favours [cont | rol] |
| | t: Z = 0.65 (| | | rest p | plot for t | he incidence of N | Contraction. | Favours [Vit A | Favours [cont | rol] |
| | t: Z = 0.65 (Experiment | 5 -5545 211 | | | plot for t | he incidence of N Odds Ratio | Contraction. | Favours [Vit A | | rol] |
| ; | Experime | ntal | The fo | 4 | | | Contraction. | | Ratio | rol] |
| tudy or Subgroup | Experime | ntal | The fo | 4 | | Odds Ratio | Contraction. | Odds | Ratio | rol] |
| tudy or Subgroup iatchoosaku 2014 | Experime Events | ntal Total | The fo Contro | I Total | Weight N | Odds Ratio I-H. Random. 95% Cl | Contraction. | Odds | Ratio | rol] |
| tudy or Subgroup iatchoosaku 2014 lactier 2012 | Experiments Events 0 | ntal Total 40 | The fo Contro Events | Total 1 40 | Weight N 1.2% | Odds Ratio I-H. Random. 95% CI 0.19 [0.01, 4.09] ← | Contraction. | Odds | Ratio | rol] |
| tudy or Subgroup iatchoosaku 2014 lactier 2012 yson 1999 | Experimen Events 0 5 | ntal Total 40 42 | The fo Contro Events 2 3 | 1 Total 40 47 | <u>Weight N</u> 1.2% 4.9% | Odds Ratio I-H. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] | Contraction. | Odds | Ratio | rol] |
| tudy or Subgroup iatchoosaku 2014 Aactier 2012 yson 1999 Vardle 2001 | Experiments Events 0 5 73 | ntal Total 40 42 405 77 | Contro Events 2 3 78 | 40 47 402 77 | Weight N 1.2% 4.9% 87.2% 6.8% | Odds Ratio LH. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] | Contraction. | Odds | Ratio | rol] |
| Test for overall effect Study or Subgroup Gatchoosaku 2014 Aactier 2012 Tyson 1999 Vardle 2001 Total (95% CI) Total events | Experiment Events 0 5 73 4 | ntal Total 40 42 405 | Contro Events 2 3 78 7 | 40 47 402 77 | Weight N 1.2% 4.9% 87.2% | Odds Ratio I-H. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] | Contraction. | Odds | Ratio | rol] |
| itudy or Subaroup Gatchoosaku 2014 Aactier 2012 yson 1999 Vardie 2001 fotal (95% CI) fotal events | Experiments Events 0 5 73 4 82 | ntal <u>40</u> 42 405 77 564 | Contro Events 2 3 78 7 90 | 40 47 402 77 566 | Weight N 1.2% 4.9% 87.2% 6.8% 100.0% | Odds Ratio LH. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] | IEC | Odds M-H. Rando | Ratio | _ |
| Situdy or Subaroup Gatchoosaku 2014 Aactier 2012 Yson 1999 Vardle 2001 Total (95% CI) Total events Iderogeneity: Tau ² = (| Experimen Events 0 5 73 4 82 0.00; Chi ² = | ntal <u>40</u> 42 405 77 564 2.65, df | Contro Events 2 3 78 7 90 | 40 47 402 77 566 | Weight N 1.2% 4.9% 87.2% 6.8% 100.0% | Odds Ratio LH. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] | IEC | Odds M-H. Rando | Ratio | |
| tudy or Subaroup iiatchoosaku 2014 factier 2012 yson 1999 Vardle 2001 iotal (95% CI) otal (95% CI) total events leterogeneity: Tau ² = (est for overall effect: 2 | Experimen Events 0 5 73 4 82 0.00; Chi ² = | ntal <u>40</u> 42 405 77 564 2.65, df = 0.53) | The fo <u>Contro</u> 2 3 78 7 90 = 3 (P = | 40 47 402 77 566 0.45); I | Weight N 1.2% 4.9% 87.2% 6.8% 100.0% ² = 0% | Odds Ratio I-H. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] — | IEC 0.1 0. Favours | Odds M-H. Rando | Ratio | |
| tudy or Subaroup iiatchoosaku 2014 factier 2012 yson 1999 Vardle 2001 iotal (95% CI) otal (95% CI) total events leterogeneity: Tau ² = (est for overall effect: 2 | Experiment Events 0 5 73 4 82 0.00; Chi ² = Z = 0.63 (P = | ntal 40 42 405 77 564 2.65, df = 0.53) | The fo <u>Contro</u> 2 3 78 7 90 = 3 (P = | 40 40 47 402 77 566 0.45); I | Weight N 1.2% 4.9% 87.2% 6.8% 100.0% ² = 0% | Odds Ratio I.H. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] | IEC 0.1 0. Favours | Odds M-H. Rando 2 0.5 1 [experimental] | Ratio m. 95% CI | |
| tudy or Subaroup iiatchoosaku 2014 factier 2012 yson 1999 Vardle 2001 iotal (95% CI) otal (95% CI) otal events leterogeneity: Tau ² = (est for overall effect: 2 | Experiment Events 0 5 73 4 82 0.00; Chi ² = 2 = 0.63 (P = Vit A | ntal 40 42 405 77 564 2.65, df = 0.53) | The fo Contro 2 3 78 7 90 = 3 (P = The for Contr | 40 47 402 77 566 0.45); I rest p ol | Weight N 1.2% 4.9% 87.2% 6.8% 100.0% 2 = 0% Dolot for to 1000000000000000000000000000000000000 | Odds Ratio I-H. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] — he incidence of I∖ Odds Ratio | IEC 0.1 0. Favours /H | Odds M-H. Rando 2 0.5 1 [experimental] | Ratio m. 95% CI - - - - - - - - - - - - - | |
| tudy or Subgroup iatchoosaku 2014 tactier 2012 yson 1999 Vardle 2001 otal (95% CI) otal events teterogeneity: Tau ² = (est for overall effect: 2) itudy or Subgroup | Experime Events 0 5 73 4 82 0.00; Chi ² = Z = 0.63 (P = Vit A Events | ntal <u>Total</u> 40 42 405 77 564 2.65, df = 0.53) Total | The fo Contro Events 2 3 78 7 90 = 3 (P = The for Contr Events | 40 47 402 77 566 0.45); I rest p ol Total | Weight N 1.2% 4.9% 4.9% 87.2% 6.8% 100.0% 2° = 0% 00 tot for tot Weight Weight | Odds Ratio I.H. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] ← he incidence of I\ Odds Ratio M-H. Random. 95% CI | IEC 0.1 0. Favours /H | Odds M-H. Rando 2 0.5 1 [experimental] | Ratio m. 95% CI | |
| tudy or Subgroup iatchoosaku 2014 lactier 2012 yson 1999 /ardle 2001 otal (95% CI) otal events leterogenelty: Tau ² = (est for overall effect: 2) tudy or Subgroup iatchoosaku 2014 | Experime Events 0 5 73 4 82 0.00; Chi ² = Z = 0.63 (P = Vit A Events 14 | ntal <u>Total</u> 40 42 405 77 564 2.65, df = 0.53) <u>Total</u> 40 | The fo <u>Contro</u> <u>Events</u> 2 3 78 7 90 = 3 (P = The fol <u>Contro</u> <u>Events</u> 17 | 40 47 402 77 566 0.45); I rest p ol <u>Total</u> 40 | Weight N 1.2% 4.9% 87.2% 6.8% 100.0% 2 = 0% blot for ti Weight 8.8% | Odds Ratio I-H. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] 0.90 [0.65, 1.25] | IEC 0.1 0. Favours /H | Odds M-H. Rando 2 0.5 1 [experimental] | Ratio m. 95% CI - - - - - - - - - - - - - | |
| tudy or Subaroup iatchoosaku 2014 lactier 2012 yson 1999 fardle 2001 otal (95% CI) otal events leterogenelty: Tau ² = (est for overall effect: 2) itudy or Subgroup liatchoosaku 2014 yson 1999 | Experime Events 0 5 73 4 82 0.00; Chi ² = Z = 0.63 (P = Vit A Events | ntal <u>Total</u> 40 42 405 77 564 2.65, df - - - - - - - - - - - - - | The fo Contro Events 2 3 78 7 90 = 3 (P = The for Contr Events | 40 47 402 77 566 0.45); I rest p ol Total 40 402 | Weight N 1.2% 4.9% 87.2% 6.8% 100.0% 2 = 0% Dolot for ti 0.0% Weight 8.8% 90.3% -3% | Odds Ratio I.H. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] .90 [0. | IEC 0.1 0. Favours /H | Odds M-H. Rando 2 0.5 1 [experimental] | Ratio m. 95% CI - - - - - - - - - - - - - | |
| tudy or Subaroup iatchoosaku 2014 iatchoosaku 2014 iatchoosaku 2014 yeon 1999 /ardle 2001 otal (95% CI) otal events eterogenelty: Tau ² = (est for overall effect: 2) tudy or Subgroup iatchoosaku 2014 yeon 1999 | Experime Events 0 5 73 4 82 0.00; Chi ² = Z = 0.63 (P = Vit A Events 14 | ntal <u>Total</u> 40 42 405 77 564 2.65, df = 0.53) <u>Total</u> 40 | The fo <u>Contro</u> <u>Events</u> 2 3 78 7 90 = 3 (P = The fol <u>Contro</u> <u>Events</u> 17 | 40 47 402 77 566 0.45); I rest p ol <u>Total</u> 40 | Weight N 1.2% 4.9% 87.2% 6.8% 100.0% 2 = 0% blot for ti Weight 8.8% | Odds Ratio I-H. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] 0.90 [0.65, 1.25] | IEC 0.1 0. Favours /H | Odds M-H. Rando 2 0.5 1 [experimental] | Ratio m. 95% CI - - - - - - - - - - - - - | |
| tudy or Subgroup iatchoosaku 2014 tactier 2012 yson 1999 /ardle 2001 otal (95% CI) otal events teterogeneity: Tau ² = (est for overall effect: 2) itudy or Subgroup iatchoosaku 2014 yson 1999 Vardle 2001 | Experime Events 0 5 73 4 82 0.00; Chi ² = Z = 0.63 (P = Vit A Events 14 | ntal 40 42 405 77 564 2.65, df = 0.53) Total 40 405 77 77 | The fo <u>Contro</u> <u>Events</u> 2 3 78 7 90 = 3 (P = The fol <u>Contro</u> <u>Events</u> 17 | 40 402 77 566 0.45); I rest p ol Total 40 402 77 | Weight N 1.2% 4.9% 4.9% 87.2% 6.8% 6.8% 100.0% 2 = 0% blot for to Weight 8.8% 90.3% 0.9% .9% | Odds Ratio I-H. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] | IEC 0.1 0. Favours /H | Odds M-H. Rando 2 0.5 1 [experimental] | Ratio m. 95% CI - - - - - - - - - - - - - | |
| tudy or Subaroup iatchoosaku 2014 Iatcier 2012 yeon 1999 Vardle 2001 otal (95% CI) otal events leterogeneity: Tau ² = (est for overall effect: 2) itudy or Subgroup iatchoosaku 2014 yson 1999 Vardle 2001 'otal (95% CI) | Experime Events 0 5 73 4 82 0.00; Chi ² = Z = 0.63 (P = Vit A Events 14 155 1 | ntal <u>Total</u> 40 42 405 77 564 2.65, df - - - - - - - - - - - - - | The fo Contro Events 2 3 78 7 90 = 3 (P = The for Contr Events 17 170 1 | 40 402 77 566 0.45); I rest p ol Total 40 402 77 | Weight N 1.2% 4.9% 87.2% 6.8% 100.0% 2 = 0% Dolot for ti 0.0% Weight 8.8% 90.3% -3% | Odds Ratio I.H. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] .90 [0. | IEC 0.1 0. Favours /H | Odds M-H. Rando 2 0.5 1 [experimental] | Ratio m. 95% CI - - - - - - - - - - - - - | |
| tudy or Subaroup iatchoosaku 2014 tactier 2012 yson 1999 vardle 2001 otal (95% CI) otal events leterogeneity: Tau ² = (est for overall effect: 2) tudy or Subgroup (iatchoosaku 2014 yson 1999 Vardle 2001 otal (95% CI) otal events | Experime Events 0 5 73 4 82 0.00; Chi ² = 2 = 0.63 (P = Vit A Events 14 155 1 170 | ntal Total 40 42 405 77 564 2.65, df = 0.53) 77 40 405 77 522 | The fo <u>Contro</u> 2 3 78 7 90 = 3 (P = The for <u>Contr</u> <u>Events</u> 177 170 1 188 | 40 47 402 77 566 0.45); I rest p ol Total 40 402 77 519 | Weight N 1.2% 4.9% 4.9% 87.2% 6.8% 6.8% 100.0% 2° = 0% blot for ti Weight 8.8% 90.3% 0.9% 100.0% | Odds Ratio I-H. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] | 0.1 0. Favours /H | Odds M-H. Rando 2 0.5 1 [experimental] Odds | Ratio m. 95% CI - - - - - - - - - - - - - | |
| C Study or Subgroup Statchoosaku 2014 Aactier 2012 yson 1999 Vardle 2001 Total (95% CI) Total events Heterogeneity: Tau ² = (est for overall effect: 2 C Study or Subgroup Study or Subgroup | Experime Events 0 5 73 4 82 0.00; Chi ² = Vit A Events 14 155 1 170 0.00; Chi ² | ntal Total 40 42 405 77 564 2.65, dfl 2.65, dfl 2.65, dfl 40 405 77 522 = 0.11, | The fo Contro Events 2 3 78 7 90 = 3 (P = The fol Contr Events 17 170 1 188 df = 2 (P | 40 47 402 77 566 0.45); I rest p ol Total 40 402 77 519 | Weight N 1.2% 4.9% 4.9% 87.2% 6.8% 6.8% 100.0% 2° = 0% blot for ti Weight 8.8% 90.3% 0.9% 100.0% | Odds Ratio I-H. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] | IEC 0.1 0. Favours /H | Odds M-H. Rando 2 0.5 1 [experimental] Odds M-H. Rando 0.2 0.5 | Ratio m. 95% CI - - - - - - - - - - - - - | 10 |
| tudy or Subaroup iiatchoosaku 2014 tactier 2012 yson 1999 Vardle 2001 iotal (95% CI) otal events leterogeneity: Tau ² = (est for overall effect: 2) itudy or Subgroup iiatchoosaku 2014 yson 1999 Yardle 2001 iotal (95% CI) iotal events leterogeneity: Tau ² = est for overall effect: | Experime Events 0 5 73 4 82 0.00; Chi ² = Vit A Events 14 155 1 170 0.00; Chi ² | ntal Total 40 42 405 77 564 2.65, df 40 405 77 522 = 0.111, = 0.112, = 0 | The fo <u>Contro</u> <u>2</u> 3 78 7 90 = 3 (P = The fol <u>Contr</u> <u>Events</u> 17 170 1 188 df = 2 (P | 40 40 47 566 0.45); I rest p ol 1 <u>Total</u> 40 402 77 519 2 = 0.95 | Weight N 1.2% 4.9% 4.9% 6.8% 100.0% 2 2 0% blot for ti Weight 8.8% 90.3% 0.9% 100.0% 5); 2 0% | Odds Ratio 1.4. Random. 95% CI 0.19 [0.01, 4.09] ← 1.96 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] | 0.1 0. Favours /H | Odds M-H. Rando 2 0.5 1 [experimental] Odds M-H. Rando 0.2 0.5 | Ratio m. 95% CI - - - - - - - - - - - - - | 10 |
| tudy or Subgroup iatchoosaku 2014 Aactier 2012 yson 1999 Vardle 2001 | Experime Events 0 5 73 4 82 0.00; Chi ² = 2 = 0.63 (P = Vit A Events 14 155 1 170 = 0.00; Chi ² Z = 1.31 (F | $\begin{array}{c} \text{final} \\ 40 \\ 42 \\ 405 \\ 77 \\ 564 \\ 2.65, df \\ 40 \\ 405 \\ 77 \\ 522 \\ = 0.11, \\ 0.15 \\ 100 \\ 1$ | The fo Contro Events 2 3 78 7 90 = 3 (P = 17 170 1 188 df = 2 (P)) he fore | 40 47 402 77 566 0.45); I rest p 60 <u>Total</u> 40 402 77 519 2 = 0.95 51 plc | Weight N 1.2% 4.9% 4.9% 6.8% 100.0% 2 2 0% blot for ti Weight 8.8% 90.3% 0.9% 100.0% 5); 2 0% | Odds Ratio 1.4. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] | 0.1 0. Favours /H | Odds M-H. Rando 2 0.5 [[experimental] Odds M-H. Rando 0.2 0.5 Favours [Vit A | Ratio m. 95% CI 2 5 Favours [control] 5 Ratio 1 2 5 Favours [control] | |
| tudy or Subaroup iatchoosaku 2014 tactier 2012 yaon 1999 Vardle 2001 iotal (95% CI) otal events leterogeneity: Tau ² = (est for overall effect: 2) itudy or Subgroup itudy or Subgroup itudy or Subgroup iotal cosaku 2014 iyson 1999 Vardle 2001 iotal (95% CI) iotal events leterogeneity: Tau ² = iest for overall effect: = | Experime Events 0 5 73 4 82 0.00; Chi ² = Z = 0.63 (P = Vit A Events 14 155 1 170 0.00; Chi ² Z = 1.31 (F Vit A | ntal 40 42 405 564 2.65, df 2.65, df 405 77 522 = 0.11, 2 = 0.11; Th | The fo Contro Events 2 3 78 7 90 = 3 (P = 17 170 1 188 df = 2 (P)) ne fore Contr | 40 40 47 402 77 566 0.45); I rest p rest p 519 2 = 0.95 st plc rol | Weight N 1.2% 4.9% 4.9% 87.2% 6.8% 100.0% a = 0% 000 for ti blot for ti 8.8% 90.3% 0.9% 100.0% 5); I ^a = 0% ot for the 6.9% | Odds Ratio 1.4. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.90 [0.65, 1.25] 0.90 [0.65, 1.25] | 0.1 0. Favours /H 0.1 0.1 0.1 0.1 | Odds M-H. Rando 2 0.5 1 [experimental] Odda M-H. Rando 0.2 0.5 Favours [Vit A Odda | Ratio m. 95% CI - - - - - - - - - - - - - | |
| tudy or Subgroup iatchoosaku 2014 lactier 2012 yson 1999 yardle 2001 otal (95% CI) otal events leterogeneity: Tau ² = (est for overall effect: 2) itudy or Subgroup itudy or Subgroup itatchoosaku 2014 yson 1999 Vardle 2001 fotal (95% CI) otal (95% CI) otal (95% CI) iotal events leterogeneity: Tau ² = est for overall effect: 2) Study or Subgroup | Experime: Events 0 5 73 4 82 0.00; Ch ² = 2 = 0.63 (P = Vit A Events 14 155 1 170 0.00; Ch ² Z = 1.31 (F Vit A Events | ntal Total 40 42 405 77 564 2.65, df 40 405 77 522 = 0.11, P = 0.11 The Total | The fo Contro Events 2 3 78 7 90 = 3 (P = The foi Contr Events 17 170 1 188 df = 2 (P)) ne fore Contro Events | I 1 40 40 47 402 77 566 00.45); I rest p ol 402 77 519 > = 0.95 st plc ol Total | Weight N 1.2% 4.9% 4.9% 6.8% 6.8% 100.0% 2 = 0% 0lot for the 0.9% 0.9% 100.0% 5); I ² = 0% 50; I ² = 0% 50; I ² = 0% | Odds Ratio I.H. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] | 0.1 0. Favours /H 0.1 0.1 0.1 0.1 | Odds M-H. Rando 2 0.5 1 [experimental] Odda M-H. Rando 0.2 0.5 Favours [Vit A Odda | Ratio m. 95% CI 2 5 Favours [control] 5 Ratio 1 2 5 Favours [control] | |
| tudy or Subaroup iatchoosaku 2014 Iactier 2012 yson 1999 ardle 2001 otal (95% CI) otal events leterogeneity: Tau ² = (est for overall effect: 2) itudy or Subgroup itudy or Subgroup itudy or Subgroup itudy or Subgroup tachoosaku 2014 yson 1999 Vardle 2001 otal (95% CI) otal events leterogeneity: Tau ² = est for overall effect: E Study or Subgroup itudy or Subgroup | Experime Events 0 5 73 4 82 0.00; Chi ² = Vit A Events 1 170 0.00; Chi ² z = 1.31 (F Vit A Events 2 2 | ntal Total 40 42 564 2.65, df 40 405 77 522 = 0.11, 0.15 Tr 15 15 15 15 | The fo Contro Events 2 3 78 7 90 = 3 (P = The for Contr Events 17 170 1 188 df = 2 (P)) ne fore Contro Events 17 170 1 188 df = 2 (P)) 188 170 188 170 188 170 188 170 188 170 188 170 188 170 188 170 170 188 170 170 170 170 170 170 170 170 | 1 Total 1 40 47 566 0.45); I rest p rest p 0 10 10 10 10 10 10 10 10 10 | Weight N 1.2% 4.9% 4.9% 8.72% 6.8% 100.0% at a straight 8.8% 90.3% 0.9% 100.0% 5); I ^a = 0% 50; I ^a = 0% 50; I ^a = 0% 50; I ^a = 0% 50; I ^a = 0% | Odds Ratio I.H. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] .90 [0.65, 1.25] .90 [0.65, 1.25] .90 [0.65, 1.25] .90 [0.65, 1.25] 0.00 [0.06, 10.28] 0.85 [0.64, 1.12] 1.00 [0.06, 16.28] 0.84 [0.64, 1.09] e incidence of sep Odds Ratio M-H. Random. 95% CI 2.05 [0.18, 23.59] | 0.1 0. Favours /H 0.1 0.1 0.1 0.1 | Odds M-H. Rando 2 0.5 1 [experimental] Odda M-H. Rando 0.2 0.5 Favours [Vit A Odda | Ratio m. 95% CI - - - - - - - - - - - - - | 10 |
| tudy or Subaroup iatchoosaku 2014 Iactier 2012 yson 1999 /ardle 2001 otal (95% CI) otal events leterogeneity: Tau ² = (est for overall effect: 2) tudy or Subgroup /ardle 2001 otal events leterogeneity: Tau ² = est for overall effect: = tudy or Subgroup otal events leterogeneity: Tau ² = est for overall effect: = | Experime Events 0 5 73 4 0.00; Chi ² = 2 = 0.63 (P = Vit A Events 14 155 1 170 0.00; Chi ² Z = 1.31 (F Vit A Events 2 5 5 | ntal 40 40 564 2.65, df = 0.53) - - - - - - - - - - - - - | The for Events 2 3 78 7 90 = 3 (P = The for Contr Events 17 170 1 188 df = 2 (P)) 10 1 188 df = 2 (P)) 1 1 1 1 1 1 1 1 1 1 1 1 1 | 40 47 402 77 566 0.45); I rest p rol Total 40 402 77 519 2 = 0.95 st plc ol Total 1 40 402 77 519 2 = 0.95 st plc 0 - 10 40 2 - 20 1 | Weight N 1.2% 4.9% 4.9% 87.2% 6.8% 100.0% 2 = 0% 0lot for ti Weight 8.8% 90.3% 0.9% 100.0% 5); I² = 0% bit for the Weight 1.6% 4.5% | Odds Ratio I.H. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] | 0.1 0. Favours /H 0.1 0.1 0.1 0.1 | Odds M-H. Rando 2 0.5 1 [experimental] Odda M-H. Rando 0.2 0.5 Favours [Vit A Odda | Ratio m. 95% CI - - - - - - - - - - - - - | 10 |
| tudy or Subaroup iatchoosaku 2014 tactier 2012 yson 1999 Yardle 2001 otal (95% CI) otal events eterogeneity: Tau ² = (est for overall effect: 2) tudy or Subgroup iatchoosaku 2014 yson 1999 Yardle 2001 iotal (95% CI) otal events leterogeneity: Tau ² = est for overall effect: E Study or Subgroup Giatchoosaku 2014 Pearson 1992 Ravishankar 2003 | Experime Events 0 5 73 4 82 0.00; Chi ² = Z = 0.63 (P = Vit A Events 14 155 1 170 0.00; Chi ² = Z = 1.31 (F Vit A Events 2 5 5 5 | ntal 40 40 564 2.65, df 564 2.65, df 40 522 = 0.11, 77 522 = 0.11, 77 522 Total 40 522 - 0.15 77 522 - 0.15 77 - 0.25 - 0.15 - 0.25 - 0.25 | The fo Contro Events 2 3 78 7 90 = 3 (P = The fol Contr Events 17 170 1 188 df = 2 (P)) ne fore Contro Events 17 170 1 188 df = 2 (P)) ne fore Contro Events 17 170 1 188 df = 2 (P)) 1 1 1 1 1 1 1 1 1 1 1 1 1 | I Iotal 40 47 402 77 5566 00.45); I rest p rol Total 400 402 77 519 2 0.45); I Total 400 402 77 519 2 0.92 st plc rol Total 400 22 18 | Weight N 1.2% 4.9% 4.9% 6.8% 100.0% 2 2 0% blot for ti Weight 8.8% 0.9% 100.0% 5); I² = 0% bt for the Neight 1.6% 4.5% 4.3% 3% | Odds Ratio 1.4. Random. 95% CI 0.19 [0.01, 4.09] ← 1.96 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] 0.90 [0.65, 1.25] | 0.1 0. Favours /H 0.1 0.1 0.1 0.1 | Odds M-H. Rando 2 0.5 1 [experimental] Odda M-H. Rando 0.2 0.5 Favours [Vit A Odda | Ratio m. 95% CI - - - - - - - - - - - - - | 10 |
| tudy or Subaroup iatchoosaku 2014 lactier 2012 yaon 1999 yardie 2001 total (95% CI) otal events leterogeneity: Tau² = (est for overall effect: 2) itudy or Subgroup itudy or Subgroup itudy or Subgroup itatchoosaku 2014 yson 1999 Vardle 2001 total (95% CI) total events leterogeneity: Tau² = eest for overall effect: = Study or Subgroup Gatchoosaku 2014 yson 1992 Avaishankar 2003 Shenai 1987 | Experime Events 0 5 73 4 0.00; Chi ² = 2 = 0.63 (P = Vit A Events 14 155 1 170 0.00; Chi ² Z = 1.31 (F Vit A Events 2 5 5 | $\begin{array}{c} \text{ntal} \\ \hline \textbf{Total} \\ 40 \\ 42 \\ 405 \\ 77 \\ 564 \\ 2.65, df \\ \hline \textbf{o} \\ 556 \\ 405 \\ 77 \\ 522 \\ \hline \textbf{o} \\ 100 \\$ | The for Events 2 3 78 7 90 = 3 (P = The for Contr Events 17 170 1 188 df = 2 (P)) 10 1 188 df = 2 (P)) 1 1 1 1 1 1 1 1 1 1 1 1 1 | 40 47 402 77 566 0.45); I rest p rol Total 40 402 77 519 2 = 0.95 st plc ol Total 1 40 402 77 519 2 = 0.95 st plc 0 - 10 40 2 - 20 1 | Weight N 1.2% 4.9% 4.9% 87.2% 6.8% 100.0% 2 = 0% 0lot for ti Weight 8.8% 90.3% 0.9% 100.0% 5); I² = 0% bit for the Weight 1.6% 4.5% | Odds Ratio I.H. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] .90 [0.65, 1.25] .90 [0.65, 1.25] .90 [0.65, 1.25] .90 [0.65, 1.25] 0.073 [0.30, 1.80] 0.85 [0.64, 1.12] 1.00 [0.06, 16.28] 0.84 [0.64, 1.09] 0.84 [0.64, 1.09] 0.84 [0.64, 1.09] 0.84 [0.64, 1.09] 0.84 [0.64, 1.09] 0.85 [0.18, 23.59] 1.02 [0.23, 4.58] 8.20 [0.40, 169.90] | 0.1 0. Favours /H 0.1 0.1 0.1 0.1 | Odds M-H. Rando 2 0.5 1 [experimental] Odda M-H. Rando 0.2 0.5 Favours [Vit A Odda | Ratio m. 95% CI - - - - - - - - - - - - - | 10 |
| tudy or Subaroup iatchoosaku 2014 lactier 2012 yson 1999 yardle 2001 otal (95% CI) otal events leterogeneity: Tau² = (est for overall effect: 2) itudy or Subgroup itudy or Subgroup iatchoosaku 2014 yson 1999 Vardle 2001 otal (95% CI) otal events leterogeneity: Tau² = est for overall effect: est for overall effect: Study or Subgroup Gatchoosaku 2014 yson 1992 wardle 2001 otal (95% CI) otal events leterogeneity: Tau² = est for overall effect: Statchoosaku 2014 varishankar 2003 shenai 1987 | Experime Events 0 5 73 4 82 0.00; Chi ² = Z = 0.63 (P = Vit A Events 14 155 1 170 0.00; Chi ² = Z = 1.31 (F Vit A Events 2 5 5 5 | ntal 40 40 564 2.65, df 564 2.65, df 40 522 = 0.11, 77 522 = 0.11, 77 522 Total 40 522 - 0.15 77 522 - 0.15 77 - 0.25 - 0.15 - 0.25 - 0.25 | The fo Contro Events 2 3 78 7 90 = 3 (P = The fol Contr Events 17 170 1 188 df = 2 (P)) ne fore Contro Events 17 170 1 188 df = 2 (P)) ne fore Contro Events 17 170 1 188 df = 2 (P)) 1 1 1 1 1 1 1 1 1 1 1 1 1 | I Iotal 40 47 402 77 5566 00.45); I rest p rol Total 400 402 77 519 2 0.45); I Total 400 402 77 519 2 0.92 st plc rol Total 400 22 18 | Weight N 1.2% 4.9% 4.9% 6.8% 100.0% 2 2 0% blot for ti Weight 8.8% 0.9% 100.0% 5); I² = 0% bt for the Neight 1.6% 4.5% 4.3% 3% | Odds Ratio 1.4. Random. 95% CI 0.19 [0.01, 4.09] ← 1.96 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] 0.90 [0.65, 1.25] | 0.1 0. Favours /H 0.1 0.1 0.1 0.1 | Odds M-H. Rando 2 0.5 1 [experimental] Odda M-H. Rando 0.2 0.5 Favours [Vit A Odda | Ratio m. 95% CI - - - - - - - - - - - - - | 10 |
| tudy or Subaroup iatchoosaku 2014 tactier 2012 yson 1999 vardle 2001 otal (95% CI) otal events leterogeneity: Tau ² = (est for overall effect: 2) tudy or Subgroup (iatchoosaku 2014 yson 1999 Vardle 2001 otal (95% CI) otal events leterogeneity: Tau ² = est for overall effect: E Study or Subgroup (iatchoosaku 2014 Pearson 1992 Ravishankar 2003 Shenai 1987 Tang 2016 | Experime: Events 0 5 73 4 82 0.00; Chi ² = Vit A Events 14 155 1 170 0.00; Chi ² Z = 1.31 (f Events 2 5 5 3 | $\begin{array}{c} \text{ntal} \\ \hline \textbf{Total} \\ 40 \\ 42 \\ 405 \\ 77 \\ 564 \\ 2.65, df \\ \hline \textbf{o} \\ 556 \\ 405 \\ 77 \\ 522 \\ \hline \textbf{o} \\ 100 \\$ | The fo Contro Events 2 3 78 7 90 = 3 (P = The foi Contr Events 17 170 1 188 df = 2 (P)) ne fore Contro Lease 1 4 4 0 | i Total 1 40 47 77 566 0.45); I rest p ol Total 40 402 77 519 P = 0.95 st plc rol Total 1 40 402 77 566 10 10 10 10 10 10 10 10 10 10 | Weight N 1.2% 4.9% 4.9% 6.8% 87.2% 6.8% 100.0% 2 = 0% blot for the 8.8% 90.3% 0.9% 100.0% 5); I ² = 0% bt for the 1.6% 4.5% 4.3% 1.0% 4.3% | Odds Ratio I.H. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] .90 [0.65, 1.25] .90 [0.65, 1.25] .90 [0.65, 1.25] .90 [0.65, 1.25] 0.073 [0.30, 1.80] 0.85 [0.64, 1.12] 1.00 [0.06, 16.28] 0.84 [0.64, 1.09] 0.84 [0.64, 1.09] 0.84 [0.64, 1.09] 0.84 [0.64, 1.09] 0.84 [0.64, 1.09] 0.85 [0.18, 23.59] 1.02 [0.23, 4.58] 8.20 [0.40, 169.90] | 0.1 0. Favours /H 0.1 0.1 0.1 0.1 | Odds M-H. Rando 2 0.5 1 [experimental] Odda M-H. Rando 0.2 0.5 Favours [Vit A Odda | Ratio m. 95% CI - - - - - - - - - - - - - | |
| Situdy or Subaroup Situdy or Su | Experime Events 0 5 73 4 82 0.00; Chi ² = Vit A Events 170 0.00; Chi ² 2 = 1.31 (F Vit A Events 2 5 5 3 4 4 170 2 170 170 170 170 170 170 170 170 | ntal Total 40 42 405 564 2.65, df 40 405 77 522 = 0.11, - 522 - - - - - - - - - - - - - | The for Events 2 3 78 7 90 = 3 (P = The for Contr Events 17 170 1 188 df = 2 (P) be fore Contr Events 17 170 1 88 df = 2 (P) be fore Control 17 170 1 88 df = 2 (P) 17 170 1 88 17 170 1 88 17 170 1 88 17 170 1 88 17 170 1 88 17 170 1 88 17 170 1 88 17 170 1 88 17 170 1 188 17 170 1 188 17 170 1 188 17 170 1 188 17 170 1 188 17 170 1 170 1 188 188 17 170 1 188 17 170 1 188 17 170 1 188 17 170 1 188 188 17 170 1 188 188 17 170 1 188 17 188 188 17 170 1 188 188 17 188 17 188 188 18 | I Total 40 47 402 77 566 0.45); I rest probl 402 77 519 2 519 2 519 2 35 t plc 40 22 18 20 32 | Weight N 1.2% 4.9% 4.9% 87.2% 6.8% 100.0% olot for th 8.8% 90.3% 0.9% 100.0% 5); I² = 0% ot for the 8.8% 90.3% 0.9% 100.0% 1.0% 4.5% 4.3% 1.0% 5.5% | Odds Ratio LH. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.95 [0.65, 1.25] 0.90 [0.65, 1.25] 0.90 [0.65, 1.25] | 0.1 0. Favours /H 0.1 0.1 0.1 0.1 | Odds M-H. Rando 2 0.5 1 [experimental] Odda M-H. Rando 0.2 0.5 Favours [Vit A Odda | Ratio m. 95% CI - - - - - - - - - - - - - | 10 |
| Study or Subaroup Gatchoosaku 2014 Aactier 2012 yson 1999 Vardie 2001 fotal (95% CI) fotal events teterogeneity: Tau ² = (iest for overall effect: 2 O Study or Subgroup Gatchoosaku 2014 Yson 1999 Vardle 2001 Total (95% CI) Study or Subgroup Kiatchoosaku 2014 Pearson 1992 Ravishankar 2003 Shenai 1987 Fang 2016 Tyson 1999 Wardle 2001 | Experime Events 0 5 73 4 0.00; Chi ² = 2 = 0.63 (P = Vit A Events 14 155 1 170 0.00; Chi ² = 2 = 1.31 (F Vit A Events 3 4 5 5 5 3 4 59 | $\begin{array}{c} \text{htal} \\ 40 \\ 42 \\ 564 \\ 77 \\ 564 \\ 2.65, df \\ 0.53 \\ 0.5$ | The fo Contro Events 2 3 78 7 90 = 3 (P = The fol Contr Events 17 170 1 188 df = 2 (P)) ie fore Contr Events 17 170 1 188 df = 2 (P)) ie fore Contro Events 5 5 5 5 5 5 5 5 5 5 5 5 5 | $\frac{1}{1000} \frac{1}{1000} \frac{1}{10000} \frac{1}{10000000000000000000000000000000000$ | Weight N 1.2% 4.9% 4.9% 87.2% 6.8% 100.0% olot for the 8.8% 90.3% 0.9% 100.0% 5); I* = 0% 50; I* = 0% 0.16% 4.5% 4.5% 4.3% 1.0% 5.5% 61.1% 21.8% 0.2% | Odds Ratio 1.4. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] 0.90 [0.65, 1.25] | 0.1 0. Favours /H 0.1 0.1 0.1 0.1 | Odds M-H. Rando 2 0.5 1 [experimental] Odda M-H. Rando 0.2 0.5 Favours [Vit A Odda | Ratio m. 95% CI - - - - - - - - - - - - - | 10 |
| tudy or Subaroup Gatchoosaku 2014 factier 2012 yson 1999 Yardle 2001 fotal events feterogeneity: Tau ² = (est for overall effect: 2 C tudy or Subgroup Katchoosaku 2014 yson 1999 Yardle 2001 fotal (95% CI) fotal events feterogeneity: Tau ² = est for overall effect: E Study or Subgroup Gatchoosaku 2014 Pearson 1999 Yardle 2001 fotal (95% CI) fotal events feterogeneity: Tau ² = fest for overall effect: E Study or Subgroup Gatchoosaku 2014 Pearson 1992 Targ 2016 Fyson 1999 Vardle 2001 Fotal (95% CI) | Experime Events 0 5 73 4 82 0.00; Chi ² = Vit A Events 14 155 1 170 0.00; Chi ² Z = 1.31 (F Vit A Events 3 4 5 1 2 2 5 5 3 4 5 5 3 4 5 5 5 3 4 5 5 5 5 3 4 5 5 5 5 5 5 5 5 5 5 5 5 5 | ntal 40 40 564 2.65, df 40 564 2.65, df 40 405 77 522 = 0.11, 77 522 = 0.11, Trial 40 2.72 2.25 40 405 502 502 2.25 502 502 502 502 502 502 502 5 | The for Events 2 3 78 7 90 = 3 (P = The for Contre Events 17 170 1 188 df = 2 (P)) ne fore Contre Events 17 170 1 188 df = 2 (P)) ne for Events 2 2 3 7 8 7 170 1 100 1 1 100 1 1 1 1 1 1 1 1 1 1 1 1 1 | $\frac{1}{1000} \frac{1}{1000} \frac{1}{10000} \frac{1}{10000000000000000000000000000000000$ | Weight N 1.2% 4.9% 4.9% 87.2% 87.2% 6.8% 100.0% 2 = 0% blot for ti 8.8% 90.3% 0.9% 100.0% 50; I² = 0% bt for the 1.6% 4.5% 4.3% 1.0% 5.5% 61.1% | Odds Ratio I.H. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] 0.90 [0.65, 1.25] 0.90 [0.65, 1.25] 0.90 [0.65, 1.25] 0.90 [0.64, 1.22] 1.00 [0.06, 16.28] 0.84 [0.64, 1.09] 0.84 [0.64, 1.09] 0.84 [0.64, 1.09] 0.84 [0.64, 1.09] 0.84 [0.64, 1.09] 1.02 [0.24, 4.38] 1.03 [0.23, 4.58] 8.20 [0.40, 11, 1.60] 0.43 [0.11, 1.60] 1.08 [0.72, 1.60] | 0.1 0. Favours /H 0.1 0.1 0.1 0.1 | Odds M-H. Rando 2 0.5 1 [experimental] Odda M-H. Rando 0.2 0.5 Favours [Vit A Odda | Ratio m. 95% CI - - - - - - - - - - - - - | |
| tudy or Subaroup iatchoosaku 2014 Iactier 2012 yson 1999 Yardle 2001 otal (95% CI) otal events leterogeneity: Tau ² = (est for overall effect: 2) tudy or Subgroup iatchoosaku 2014 yson 1999 Yardle 2001 otal (95% CI) otal events leterogeneity: Tau ² = est for overall effect: E tudy or Subgroup (iatchoosaku 2014 'earson 1992 Ravishankar 2003 ishenai 1987 'ang 2016 'yson 1999 Vardle 2001 'otal (95% CI) 'otal events | Experime Events 0 5 73 4 0.00; Ch ² = 2 = 0.63 (P = Vit A Events 14 155 1 170 0.00; Ch ² Z = 1.31 (F Vit A Events 2 5 3 4 59 25 3 4 59 25 3 4 | ntal 40 40 564 2.65, df = 0.53) - - - - - - - - - - - - - | The for Events 2 3 78 7 90 = 3 (P = The for Contr Events 17 170 1 1888 df = 2 (P)) ne fore Contr Events 17 170 1 1888 df = 2 (P)) ne for Contr Events 2 17 17 17 17 17 17 17 17 17 17 | I I I 40 40 47 402 77 566 9 old 556 old 556 old 77 566 9 old Total 400 402 77 519 2 0.95 st plc 10 20 18 20 32 402 77 611 611 | Weight N 1.2% 4.9% 4.9% 87.2% 6.8% 100.0% 2 = 0% 0lot for th 0lot for th 8.8% 90.3% 0.9% 100.0% 5.5% 61.1% 5.5% 61.1% 21.8% 100.0% 5.5% | Odds Ratio 1.4. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] 0.90 [0.65, 1.25] | 0.1 0. Favours /H | Odds M-H. Rando | Ratio m. 95% CI - - - - - - - - - - - - - | 10 10 |
| tudy or Subaroup iatchoosaku 2014 tactier 2012 yson 1999 yardle 2001 otal (95% CI) otal events leterogeneity: Tau ² = (est for overall effect: 2) tudy or Subgroup tiatchoosaku 2014 yson 1999 Yardle 2001 otal (95% CI) otal events leterogeneity: Tau ² = est for overall effect: E Study or Subgroup tiatchoosaku 2014 Yearson 1999 Yardle 2001 otal 1987 ang 2016 Yyson 1999 Vardle 2001 Total (95% CI) | Experime: Events 0 5 73 4 82 0.00; Chi ² = Vit A Events 14 155 1 170 0.00; Chi ² = 2 5 5 3 4 59 25 103 = 0.00; Chi ² | $\begin{array}{c} \text{htal} \\ \hline \textbf{Total} \\ 40 \\ 42 \\ 405 \\ 77 \\ 564 \\ 2.65, \text{ df} \\ \hline \textbf{o} \\ 556 \\ 405 \\ 77 \\ 522 \\ \hline \textbf{o} \\ 405 \\ 77 \\ 522 \\ \hline \textbf{o} \\ 1 \\ \hline \textbf{o} \\ 1 \\ \hline \textbf{o} \\ 27 \\ 77 \\ \hline \textbf{o} \\ 20 \\ 32 \\ 405 \\ 77 \\ 623 \\ \hline \textbf{e} \\ 43 \\ 43 \\ 623 \\ \hline \textbf{e} \\ 43 \\ 64 \\ 32 \\ 77 \\ 623 \\ \hline \textbf{e} \\ 43 \\ 64 \\ 32 \\ 77 \\ 623 \\ \hline \textbf{e} \\ 43 \\ 64 \\ 77 \\ 77 \\ 64 \\ 77 \\ 77 \\ 70 \\ 70 \\ 70 \\ 70 \\ 70 \\ 7$ | The fo Contro Events 2 3 78 7 90 = 3 (P = The foi Contr Events 17 170 1 188 df = 2 (P)) n e fore Contro 1 4 4 0 8 55 29 101 df = 6 (F | I I I 40 40 47 402 77 566 9 old 556 old 556 old 77 566 9 old Total 400 402 77 519 2 0.95 st plc 10 20 18 20 32 402 77 611 611 | Weight N 1.2% 4.9% 4.9% 87.2% 6.8% 100.0% 2 = 0% 0lot for th 0lot for th 8.8% 90.3% 0.9% 100.0% 5.5% 61.1% 5.5% 61.1% 21.8% 100.0% 5.5% | Odds Ratio 1.4. Random. 95% CI 0.19 [0.01, 4.09] ← 1.98 [0.44, 8.85] 0.91 [0.64, 1.30] 0.55 [0.15, 1.95] 0.90 [0.65, 1.25] 0.90 [0.65, 1.25] | 0.1 0. Favours /H 0.1 0.1 0.1 0.1 | Odds I M-H. Rando 2 0.5 [[experimental] 0dd: M-H. Rando 0dd: M-H. Rando 0dd: 0.2 0.5 [Favours [Vit A Odd: 0.2 0.2 | Ratio m. 95% CI - - - - - - - - - - - - - | 10 10 |





Previous studies^[30,31] have suggested that vitamin A activates SP-B mRNA transcription through the RA-RAR/RXR pathway and tissue-specific thyroid transcription factor (TTF-1) and other factors, increasing SP-B expression. Several reports^[32,33] have shown that the lack of vitamin A can cause the content of SP-A, SP-B, and SP-C mRNAs to decrease, and at the same time reduce the expression of fatty acid synthase (FAS) gene, thus affecting the synthesis of phospholipid precursors. Vitamin A may increase phospholipid and lung surfactant protein synthesis through the above two pathways to promote the lung surfactant synthesis, and thus promotes lung development and maturity.^[34] In addition, it may be related to the antioxidant protection of vitamin A and the promotion of repair mechanisms after lung injury.^[35]

With the use of clinical vitamin A, reports on its adverse reactions have also emerged. The pain and sepsis are the two most commonly see adverse reaction.^[36] Therefore, not only the efficacy of vitamin A, but also its safety in premature infants is

worthy of attention and discussion. Previous studies have shown that vitamin A can reduce the incidence of BPD in preterm infants without serious adverse reactions,^[37] but Chabra et al^[38] have observed an increase in the incidence of infection and sepsis in children receiving vitamin A. The relevant complications of the two groups of patients in the included nine RCTs are not significantly different. This shows that supplementing vitamin A to prevent BPD in preterm infants may be safe, but further verification is still necessary. Previous experiments^[39,40] in rats have found that vitamin A

has a significant effect on lung differentiation and maturation, mainly in the following two aspects. In contrast, lack of vitamin A can cause metaplasia of trachea and bronchial squamous epithelium, and supplementation of vitamin A-related agents can improve its morphological changes.^[41] In contrast, vitamin A can affect lung gene expression.^[42] Retinyl esters, RBP, and retinoic acid binding proteins can accumulate in the lungs. At the same time, some vitamin A subtypes are expressed in the lungs. The expression of the aforementioned proteins and retinoic acid regulated genes has relevance. If the retinyl ester in the lung is obviously consumed, the cellular RBP level will change significantly, indicating that vitamin A is involved in lung development. Some scholars^[43] supplemented the animal model of BPD of premature lambs with vitamin A and have found that it can improve alveolar formation and alveolar capillary growth, reduce the expression of pulmonary parenchymal elastin messenger ribonucleotides and the accumulation of elastic fibers, and achieve better gas exchange. At the same time, some scholars^[44] believe that vitamin A deficiency may be one of the reasons for the delayed embryonic lung development in rats by monitoring the levels of related proteins in the rats with absence of fetal lung development. The purpose of this study is to evaluate the effects and safety of BPD by vitamin A. However, the diagnosis can only be made when the oxygen is inhaled 28 days after birth or corrected for gestational age of 36 weeks.^[45] Therefore, the focus should also be put on the prevention of BPD.

Several limitations of this present study should be considered. First, the number of high-quality studies on the role of vitamin A in premature infants remains limited, and we failed to conduct subgroup analyses on the results of ROP, future studies with rigorous design are needed. Secondly, the included studies did not observe the long-term neurodevelopment on the painful stimuli caused by repeated intramuscular injections. The longer followup periods are needed. Thirdly, the dose of vitamin A in the nine RCTs included in this study varied from 1500 to 10,000 IU, the dose and effect between vitamin A and related outcomes should be further elucidated in the future.

5. Conclusions

In conclusion, vitamin A supplementation is beneficial to reduce BPD in premature infants, and there are no significant differences on the incidence of ROP, NEC, IVH, sepsis, and mortality between two groups. Vitamin A supplementation may be a viable option for the prophylaxis of BPD in premature infants. However, at present, there is still a lack of evidence-based evidence on the administration approaches and dosages of supplementing vitamin A. Limited by the number and quality of included studies, the role of vitamin A in premature infants should be further clarified by more high-quality studies.

Author contributions

Y D designed research; Y D, Z C conducted research; Y D, Y L analyzed data; Y D wrote the first draft of manuscript; Y D had primary responsibility for final content. All authors read and approved the final manuscript. Conceptualization: Yueqin Ding, Zhifeng Chen, Yanling Lu. Data curation: Yueqin Ding. Formal analysis: Yueqin Ding, Zhifeng Chen. Investigation: Yueqin Ding, Yanling Lu. Methodology: Yueqin Ding, Zhifeng Chen, Yanling Lu. Project administration: Yueqin Ding, Zhifeng Chen. Resources: Yueqin Ding, Yanling Lu. Software: Yueqin Ding, Zhifeng Chen, Yanling Lu. Supervision: Yueqin Ding. Validation: Yueqin Ding. Visualization: Yueqin Ding, Zhifeng Chen. Writing - original draft: Yueqin Ding, Zhifeng Chen.

Writing – review & editing: Yueqin Ding.

References

- Tracy MK, Berkelhamer SK. Bronchopulmonary dysplasia and pulmonary outcomes of prematurity. Pediatr Ann 2019;48:e148–53.
- [2] Gonzalez-Luis GE, van Westering-Kroon E, Villamor-Martinez E, et al. Tobacco smoking during pregnancy is associated with increased risk of moderate/severe bronchopulmonary dysplasia: a systematic review and meta-analysis. Front Pediatr 2020;8:160.
- [3] Haggie S, Robinson P, Selvadurai H, et al. Bronchopulmonary dysplasia: a review of the pulmonary sequelae in the post-surfactant era. J Paediatr Child Health 2020;56:680–9.
- [4] Thebaud B, Kourembanas S. Can we cure bronchopulmonary dysplasia? J Pediatr 2017;191:12–4.
- [5] Jensen EA, Roberts RS, Schmidt B. Drugs to prevent bronchopulmonary dysplasia: effect of baseline risk on the number needed to treat. J Pediatr 2020.
- [6] Naeem A, Ahmed I, Silveyra P. Bronchopulmonary dysplasia: an update on experimental therapeutics. Eur Med J (Chelmsf) 2019;4:20–9.
- [7] Shenai JP, Kennedy KA, Chytil F, et al. Clinical trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia. J Pediatr 1987;111:269–77.
- [8] Tolia VN, Murthy K, McKinley PS, et al. The effect of the national shortage of vitamin A on death or chronic lung disease in extremely lowbirth-weight infants. JAMA Pediatr 2014;168:1039–44.
- [9] Araki S, Kato S, Namba F, et al. Vitamin A to prevent bronchopulmonary dysplasia in extremely low birth weight infants: a systematic review and meta-analysis. PLoS One 2018;13:e0207730.
- [10] Strueby L, Thebaud B. Novel therapeutics for bronchopulmonary dysplasia. Curr Opin Pediatr 2018;30:378–83.
- [11] Panic N, Leoncini E, de Belvis G, et al. Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses. PLoS One 2013;8:e83138.
- [12] Jorgensen L, Paludan-Muller AS, Laursen DR, et al. Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews. Syst Rev 2016;5:80.
- [13] Kiatchoosakun P, Jirapradittha J, Panthongviriyakul MC, et al. Vitamin A supplementation for prevention of bronchopulmonary dysplasia in very-low-birth-weight premature Thai infants: a randomized trial. J Med Assoc Thai 2014;97(Suppl 10):S82–88.
- [14] Mactier H, McCulloch DL, Hamilton R, et al. Vitamin A supplementation improves retinal function in infants at risk of retinopathy of prematurity. J Pediatr 2012;160:954–9. e951.
- [15] Pearson E, Bose C, Snidow T, et al. Trial of vitamin A supplementation in very low birth weight infants at risk for bronchopulmonary dysplasia. J Pediatr 1992;121:420–7.
- [16] Ravishankar C, Nafday S, Green RS, et al. A trial of vitamin A therapy to facilitate ductal closure in premature infants. J Pediatr 2003;143: 644–8.

- [17] Tang J, Li Z, Zou Y, et al. Clinical study on the prevention of neonatal bronchopulmonary dysplasia with high-dose vitamin A. Health Res 2016;36:533–5.
- [18] Tyson JE, Wright LL, Oh W, et al. Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 1999;340:1962–8.
- [19] Wardle SP, Hughes A, Chen S, et al. Randomised controlled trial of oral vitamin A supplementation in preterm infants to prevent chronic lung disease. Arch Dis Child Fetal Neonatal Ed 2001;84:F9–13.
- [20] Werkman SH, Peeples JM, Cooke RJ, et al. Effect of vitamin A supplementation of intravenous lipids on early vitamin A intake and status of premature infants. Am J Clin Nutr 1994;59:586–92.
- [21] Timoneda J, Rodriguez-Fernandez L, Zaragoza R, et al. Vitamin A deficiency and the lung. Nutrients 2018;10:
- [22] Schwartz E, Zelig R, Parker A, et al. Vitamin A supplementation for the prevention of bronchopulmonary dysplasia in preterm infants: an update. Nutr Clin Pract 2017;32:346–53.
- [23] Mactier H. Vitamin A for preterm infants; where are we now? Semin Fetal Neonatal Med 2013;18:166–71.
- [24] Kalikkot Thekkeveedu R, Guaman MC, Shivanna B. Bronchopulmonary dysplasia: a review of pathogenesis and pathophysiology. Respir Med 2017;132:170–7.
- [25] Bancalari E, Jain D. Bronchopulmonary dysplasia: 50 years after the original description. Neonatology 2019;115:384–91.
- [26] Shah PS, Lui K, Sjors G, et al. Neonatal outcomes of very low birth weight and very preterm neonates: an international comparison. J Pediatr 2016;177:144–52. e146.
- [27] Gemmell L, Martin L, Murphy KE, et al. Hypertensive disorders of pregnancy and outcomes of preterm infants of 24 to 28 weeks' gestation. J Perinatol 2016;36:1067–72.
- [28] Dowling JE. Vitamin A: its many roles-from vision and synaptic plasticity to infant mortality. J Comp Physiol A Neuroethol Sens Neural Behav Physiol 2020;206:389–99.
- [29] Sharma A, Xin Y, Chen X, et al. Early prediction of moderate to severe bronchopulmonary dysplasia in extremely premature infants. Pediatr Neonatol 2019.
- [30] Tillis CC, Huang HW, Bi W, et al. Glucocorticoid regulation of human pulmonary surfactant protein-B (SP-B) mRNA stability is independent of activated glucocorticoid receptor. Am J Physiol Lung Cell Mol Physiol 2011;300:L940–50.
- [31] Deng M, Tufan T, Raza MU, et al. MicroRNAs 29b and 181a downregulate the expression of the norepinephrine transporter and glucocorticoid receptors in PC12 cells. J Neurochem 2016;139:197–207.

- [32] Gawronski CA, Gawronski KM. Vitamin A supplementation for prevention of bronchopulmonary dysplasia: cornerstone of care or futile therapy? Ann Pharmacother 2016;50:680–4.
- [33] Zheng J, He Q, Tang H, et al. Overexpression of miR-455-5p affects retinol (vitamin A) absorption by downregulating STRA6 in a nitrofen-induced CDH with lung hypoplasia rat model. Pediatr Pulmonol 2020;55:1433–9.
- [34] Pein H, Koeberle SC, Voelkel M, et al. Vitamin A regulates Akt signaling through the phospholipid fatty acid composition. FASEB J 2017;31: 4566–77.
- [35] Kim HJ, Sparrow JR. Bisretinoid phospholipid and vitamin A aldehyde: shining a light. J Lipid Res 2020.
- [36] McGill JL, Kelly SM, Guerra-Maupome M, et al. Vitamin A deficiency impairs the immune response to intranasal vaccination and RSV infection in neonatal calves. Sci Rep 2019;9:15157.
- [37] Shen T, Bimali M, Faramawi M, et al. Consumption of vitamin K and vitamin A are associated with reduced risk of developing emphysema: NHANES 2007-2016. Front Nutr 2020;7:47.
- [38] Chabra S, Mayock DE, Zerzan J, et al. Vitamin A status after prophylactic intramuscular vitamin A supplementation in extremely low birth weight infants. Nutr Clin Pract 2013;28:381–6.
- [39] Ravichandran R, Viswanathan S, Berlin Grace VM, et al. Ameliorating effect of lipo-ATRA treatment on the expression of TIG3 and its suppressing effect on PPARgamma gene expression in lung cancer animal model. Mol Cell Biochem 2019;460:105–12.
- [40] Cui W, Zhang W, Yuan X, et al. Vitamin A deficiency execrates Lewis lung carcinoma via induction of type 2 innate lymphoid cells and alternatively activates macrophages. Food Sci Nutr 2019;7:1288–94.
- [41] Symowski C, Voehringer D. Interactions between innate lymphoid cells and cells of the innate and adaptive immune system. Front Immunol 2017;8:1422.
- [42] Kumbhar S, Khan AZ, Parveen F, et al. Impacts of selenium and vitamin E supplementation on mRNA of heat shock proteins, selenoproteins and antioxidants in broilers exposed to high temperature. AMB Express 2018;8:112.
- [43] Wahl HB, Hutten MC, Monz D, et al. Vitamin A supplementation by endotracheal application of a nano-encapsulated preparation is feasible in ventilated preterm lambs. J Aerosol Med Pulm Drug Deliv 2018;31:323–30.
- [44] Giridhar S, Kumar J, Attri SV, et al. Intramuscular followed by oral vitamin A supplementation in neonates with birth weight from 750 to 1250 g: a randomized controlled trial. Indian J Clin Biochem 2020;35:197–204.
- [45] Huang J, Zhang L, Tang J, et al. Human milk as a protective factor for bronchopulmonary dysplasia: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2019;104:F128–36.